TELEMONITORING significantly improved self-care and medication adherence in patients with heart failure (HF), according to a new randomised clinical trial.
HF remains a leading cause of hospitalisation and reduced quality of life worldwide, with poor self-care and medication adherence contributing to adverse outcomes. As digital health technologies advance, telemonitoring has emerged as a potential strategy to support patients outside traditional clinical settings.
Telemonitoring Improves Heart Failure Self-Care and Medication Adherence
In this parallel randomised clinical trial, researchers evaluated the impact of telemonitoring on clinical outcomes in 136 patients with HF. Participants were allocated to either an intervention group receiving structured telemonitoring, education, and weekly follow-up for eight weeks, or a control group receiving standard care. Of these, 123 patients completed the study.
Self-care, measured using the European Heart Failure Self-Care Behaviour Scale, improved significantly in the telemonitoring group compared with controls (p<0.001), with a large effect size (Cohen’s d: −1.26; 95% CI: −1.64–−0.87). Medication adherence, assessed using the Medication Adherence Rating Scale, also showed significant improvement (p<0.001), with a moderate-to-large effect size (Cohen’s d: 0.73; 95% CI: 0.37–1.10).
Baseline characteristics were comparable between groups, strengthening the validity of the findings.
Digital Follow-Up and Education Empowers Patients
Telemonitoring interventions combined remote monitoring with patient education and consistent follow-up, aiming to improve patients’ understanding of their condition and encourage active participation in care. Improved self-care behaviours, such as symptom monitoring and lifestyle adjustments, are critical in HF management and may help reduce hospital admissions.
The findings suggest that structured, technology-based follow-up can play a meaningful role in enhancing patient engagement, particularly in chronic conditions requiring long-term management.
Limitations and Future Directions
Despite promising results, the intervention period was relatively short at eight weeks, and long-term sustainability of the observed benefits remains uncertain. Additionally, the sample size was modest, and further large-scale trials are needed to confirm these findings across diverse populations.
Nevertheless, the study highlights the growing potential of telemonitoring to complement conventional care. Future research should explore its long-term impact on hospitalisation rates, mortality, and healthcare costs, as well as strategies to integrate these tools into routine clinical practice.
As healthcare systems increasingly adopt digital solutions, telemonitoring may offer a scalable approach to improving outcomes in patients with HF.
Reference
Shahbazi Z et al. Effectiveness of telemonitoring on clinical outcomes in patients with heart failure: a randomized clinical trial. Sci Rep. 2026;DOI:10.1038/s41598-026-49399-x.
Featured image: Thidaphon on Adobe Stock
